When the Rubber Meets the Road: Adherence and Persistence with Non-Vitamin K Antagonist Oral Anticoagulants and Old Oral Anticoagulants in the Real World-A Problem or A Myth ?

Seminars in Thrombosis and Hemostasis

Volumn 89, Issue 1, 2014, Pages 852-859

  Suryanarayan, Deepa ^a   Schulman, Sam ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

adherence; anticoagulant therapy; persistence

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT; UNCLASSIFIED DRUG; ACETYLSALICYLIC ACID; APIXABAN; CLOPIDOGREL; EDOXABAN; RIVAROXABAN; WARFARIN; XIMELAGATRAN; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); HUMAN; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; META ANALYSIS (TOPIC); PATIENT COMPLIANCE; PATIENT EDUCATION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); THROMBOEMBOLISM; ATRIAL FIBRILLATION; EMBOLISM; HEART VALVE PROSTHESIS; OUTCOME ASSESSMENT; SECONDARY PREVENTION; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; VITAMIN K;

EID: 84939434311     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1395156     Document Type: Article

References (62)

1. Mueller R. L., Scheidt S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation: 1994; 89 1 432 449
2. Fareed J., Hoppensteadt D. A., Fareed D., et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost: 2008; 34 1 58 73
3. Husted S., de Caterina R., Andreotti F., et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost: 2014; 111 5 781 782
4. Rojas-Hernandez C. M., Garcia D. A. The novel oral anticoagulants. Semin Thromb Hemost: 2013; 39 2 117 126
5. Hippocrates. Decorum, XVI. In: Jones W. H., ed. Hippocrates with an English Translation. London Heinemann: 1923
6. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med: 2005; 353 5 487 497
7. Claxton A. J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther: 2001; 23 8 1296 1310
8. Fischer M. A., Stedman M. R., Lii J., et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med: 2010; 25 4 284 290
9. Simpson S. H., Eurich D. T., Majumdar S. R., et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ: 2006; 333 7557 15
10. Peidro-Garcés L., Otero-Fernandez R., Lozano-Lizarraga L. Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study [in Spanish]. Rev Esp Cir Ortop Traumatol: 2013; 57 1 53 60
11. World Health Organization Adherence to long-term therapies: evidence for action. Available at: http://www.who.int/chp/knowledge/publications/adherence-report/en/. Accessed August 2, 2014
12. Doggrell S. A. Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help? Drugs Aging: 2010; 27 3 239 254
13. Holbrook A., Schulman S., Witt D. M., et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest: 2012; 141 2 Suppl e152S e84S
14. Levi M., de Peuter O. R., Kamphuisen P. W. Management strategies for optimal control of anticoagulation in patients with atrial fibrillation. Semin Thromb Hemost: 2009; 35 6 560 567
15. Waterman A. D., Milligan P. E., Bayer L., Banet G. A., Gatchel S. K., Gage B. F. Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm: 2004; 61 12 1258 1264
16. Chen S. Y., Wu N., Gulseth M., et al. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events. J Manag Care Pharm: 2013; 19 4 291 301
17. Gallagher A. M., Setakis E., Plumb J. M., Clemens A., van Staa T. P. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost: 2011; 106 5 968 977
18. Mant J., Hobbs F. D., Fletcher K., et al. BAFTA investigators. Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet: 2007; 370 9586 493 503
19. Hylek E. M., Evans-Molina C., Shea C., Henault L. E., Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation: 2007; 115 21 2689 2696
20. De Schryver E. L., van Gijn J., Kappelle L. J., Koudstaal P. J., Algra A. Dutch TIA trial and SPIRIT study groups Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol: 2005; 252 11 1316 1321
21. Davis N. J., Billett H. H., Cohen H. W., Arnsten J. H. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother: 2005; 39 4 632 636
22. Fang M. C., Go A. S., Chang Y., Borowsky L., Pomernacki N. K., Singer D. E. ATRIA Study Group Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol: 2008; 51 8 810 815
23. Levi M., Hobbs F. D., Jacobson A. K., et al. Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. Semin Thromb Hemost: 2009; 35 6 527 542
24. Arnsten J. H., Gelfand J. M., Singer D. E. Determinants of compliance with anticoagulation: A case-control study. Am J Med: 1997; 103 1 11 17
25. Nikolaus T., Kruse W., Bach M., Specht-Leible N., Oster P., Schlierf G. Elderly patients' problems with medication. An in-hospital and follow-up study. Eur J Clin Pharmacol: 1996; 49 4 255 259
26. Kimmel S. E., Chen Z., Price M., et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med: 2007; 167 3 229 235
27. Platt A. B., Localio A. R., Brensinger C. M., et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf: 2008; 17 9 853 860
28. Salmela B., Joutsi-Korhonen L., Armstrong E., Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost: 2012; 38 1 23 30
29. Larsen T. B., Rasmussen L. H., Skjoth F., et al. Efficacy and safety of dabigatran etexilate and warfarin in real-world patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol: 2013; 61 22 2264 2273
30. Coleman C. I., Limone B., Sobieraj D. M., et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm: 2012; 18 7 527 539
31. Thorne K., Jayathissa S., Dee S., et al. Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice. Intern Med J: 2014; 44 3 261 265
32. Zalesak M., Siu K., Francis K., et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes: 2013; 6 5 567 574
33. Stanek E. J., Agatep B. C., Herrera V., et al. Assessment of initial U.S. dabigatran utilization and short-term persistence. Circulation: 2011; 124 (21, Supplement): A16675
34. Michel J., Mundell D., Boga T., Sasse A. Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. Heart Lung Circ: 2013; 22 1 50 55
35. Lee P. Y., Han S. Y., Miyahara R. K. Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care. Am J Health Syst Pharm: 2013; 70 13 1154 1161
36. Schulman S., Shortt B., Robinson M., Eikelboom J. W. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost: 2013; 11 7 1295 1299
37. Shore S., Carey E. P., Turakhia M. P., et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J: 2014; 167 6 810 817
38. Walenga J. M., Hoppensteadt D. A. Monitoring the new antithrombotic drugs. Semin Thromb Hemost: 2004; 30 6 683 695
39. Wong P. Y., Schulman S., Woodworth S., Holbrook A. Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis. J Thromb Haemost: 2013; 11 3 491 502
40. Roumie C. L., Elasy T. A., Greevy R., et al. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann Intern Med: 2006; 145 3 165 175
41. Balamurugan A., Ohsfeldt R., Hughes T., Phillips M. Diabetes self-management education program for Medicaid recipients: a continuous quality improvement process. Diabetes Educ: 2006; 32 6 893 900
42. Heidbuchel H., Verhamme P., Alings M., et al. European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace: 2013; 15 5 625 651
43. Bangalore S., Kamalakkannan G., Parkar S., Messerli F. H. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med: 2007; 120 8 713 719
44. Hussein M. A., Chapman R. H., Benner J. S., et al. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study. Am J Cardiovasc Drugs: 2010; 10 3 193 202
45. Liu Q., Abba K., Alejandria M. M., Balanag V. M., Berba R. P., Lansang M. A. Reminder systems and late patient tracers in the diagnosis and management of tuberculosis. Cochrane Database Syst Rev: 2008; 4 CD006594
46. Wei J., Hollin I., Kachnowski S. A review of the use of mobile phone text messaging in clinical and healthy behaviour interventions. J Telemed Telecare: 2011; 17 1 41 48
47. Connolly S., Pogue J., Hart R., et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet: 2006; 367 9526 1903 1912
48. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol: 1997; 42 6 857 865
49. Olsson S. B. Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet: 2003; 362 9397 1691 1698
50. Albers G. W., Diener H. C., Frison L., et al. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA: 2005; 293 6 690 698
51. Connolly S. J., Ezekowitz M. D., Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
52. Schulman S., Kearon C., Kakkar A. K., et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med: 2009; 361 24 2342 2352
53. Schulman S., Kakkar A. K., Goldhaber S. Z., et al. RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation: 2014; 129 7 764 772
54. Schulman S., Kearon C., Kakkar A. K., et al. RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med: 2013; 368 8 709 718
55. Patel M. R., Mahaffey K. W., Garg J., et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
56. Bauersachs R., Berkowitz S. D., Brenner B., et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med: 2010; 363 26 2499 2510
57. Büller H. R., Prins M. H., Lensin A. W., et al. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med: 2012; 366 14 1287 1297
58. Agnelli G., Buller H. R., Cohen A., et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med: 2013; 369 9 799 808
59. Agnelli G., Buller H. R., Cohen A., et al. PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med: 2013; 368 8 699 708
60. Granger C. B., Alexander J. H., McMurray J. J., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
61. Giugliano R. P., Ruff C. T., Braunwald E., et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2013; 369 22 2093 2104
62. Büller H. R., Décousus H., Grosso M. A., et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med: 2013; 369 15 1406 1415